Soemiwati Holland, MD
Endocrinology, Diabetes & Metabolism · Jackson, NJNPI 1740549864
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,599 of the $17,572 with a category attached, or 66.0%. 42 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 39.9% of the total. Reporting peaked in 2024 at $8,458 and has fallen 69.0% since, to $2,620 in 2025.
Across 734 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$7K
- Novo Nordisk$2K
- Abbott$1K
- Corcept Therapeutics$950
- Lilly USA, LLC$860
- Amgen$728
- plus $5K from 36 others
What the payments were for
- Speaking & faculty fees$5,86433%
- Food & beverage$11,59966%
- Education$500%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 44 | $7,012 |
| Novo Nordisk | 189 | $2,150 |
| Abbott | 51 | $1,064 |
| Corcept Therapeutics | 58 | $950 |
| Lilly USA, LLC | 58 | $860 |
| Amgen(2 entities) | 48 | $728 |
| Mannkind Corporation | 37 | $683 |
| Dexcom, Inc. | 27 | $502 |
| AstraZeneca(2 entities) | 23 | $338 |
| AbbVie | 19 | $306 |
| Recordati_rare_diseases_inc. | 15 | $279 |
| Embecta Corp. | 17 | $217 |
| Amneal Pharmaceuticals LLC | 14 | $216 |
| Xeris Pharmaceuticals, Inc. | 15 | $202 |
| Insulet Corporation | 9 | $196 |
| Pfizer | 10 | $192 |
| Boehringer Ingelheim | 13 | $177 |
| Bayer | 10 | $172 |
| Medtronic(2 entities) | 10 | $165 |
| Ipsen Biopharmaceuticals, Inc | 6 | $108 |
| Ascendis Pharma Endocrinology Inc | 6 | $99 |
| UCB, Inc. | 7 | $96 |
| Madrigal Pharmaceuticals | 4 | $94 |
| IBSA Pharma Inc. | 7 | $90 |
| Chiesi USA, Inc. | 4 | $84 |
| Radius Health, Inc. | 5 | $80 |
| Antares Pharma, Inc. | 2 | $79 |
| Tandem Diabetes Care, Inc. | 4 | $73 |
| Amarin Pharma, Inc. | 3 | $43 |
| BD | 3 | $43 |
| Cequr Corporation | 1 | $39 |
| Ionis Pharmaceuticals, Inc. | 2 | $36 |
| Tolmar, Inc. | 2 | $33 |
| Amryt Pharma Holdings Ltd | 2 | $33 |
| Merck | 2 | $26 |
| Soleno Therapeutics, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Viiv Healthcare Company | 1 | $14 |
| Lifescan, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$6,281
- AFREZZA$150
- FREESTYLE LIBRE 3$136
How this compares
$17,572 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $296,665 |
| JardianceEmpagliflozin | 119 | $139,689 |
| MounjaroTirzepatide | 41 | $76,470 |
| FarxigaDapagliflozin Propanediol | 53 | $69,777 |
| Humalog Kwikpen U-200Insulin Lispro | 25 | $67,707 |
| TrulicityDulaglutide | 39 | $58,421 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $55,986 |
| RybelsusSemaglutide | 27 | $44,777 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $25,848 |
| JanuviaSitagliptin Phosphate | 21 | $25,351 |
| TradjentaLinagliptin | 25 | $24,648 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $17,520 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $16,802 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $15,724 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $13,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $2,150 | $355,339207 claims |
| Boehringer IngelheimJardiance, Tradjenta | $177 | $164,337144 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $860 | $143,333100 claims |
| AstraZenecaFarxiga | $338 | $69,77753 claims |
| MerckJanuvia, Janumet | $26 | $42,87136 claims |
| AbbVieSynthroid | $306 | $7,99680 claims |
| IBSA Pharma Inc.Tirosint | $90 | $7,06034 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $216 | $3,704289 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Jackson
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.